Patent application number | Description | Published |
20080299173 | CHONDROCYTE CONTAINER AND METHOD OF USE - Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the cell chamber can be configured such that a portion of cells can be positioned at least about 1.5 mm from an external wall of the device (i.e., about 1.5 mm away from an external nutrient supply). For example, the cell chamber can have a tubular configuration having a length and a diameter wherein each of these dimensions is at least about 3 mm (thereby the central core to the chamber is at least about 1.5 mm from the outer wall of the device). | 12-04-2008 |
20090162386 | CHONDROCYTE THERAPEUTIC DELIVERY SYSTEM - Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes. | 06-25-2009 |
20110091517 | BIOCOMPATIBLE SCAFFOLDS WITH TISSUE FRAGMENTS - A biocompatible tissue repair implant or scaffold device is provided for use in repairing a variety of tissue injuries, particularly injuries to cartilage, ligaments, tendons, and nerves. The repair procedures may be conducted with implants that contain a biological component that assists in healing or tissue repair. The biocompatible tissue repair implants include a biocompatible scaffold and particles of living tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold. | 04-21-2011 |
20120189619 | METHODS FOR TREATING A SPINAL DISORDER OR OSTEOARTHRITIS USING DOMINANT NEGATIVE TISSUE NECROSIS FACTOR - Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro®-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation. | 07-26-2012 |
20120302958 | CHONDROCYTE CONTAINER AND METHOD OF USE - Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the cell chamber can be configured such that a portion of cells can be positioned at least about 1.5 mm from an external wall of the device (i.e., about 1.5 mm away from an external nutrient supply). For example, the cell chamber can have a tubular configuration having a length and a diameter wherein each of these dimensions is at least about 3 mm (thereby the central core to the chamber is at least about 1.5 mm from the outer wall of the device). | 11-29-2012 |
20140081209 | Chondrocyte Container and Method of Use - Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the cell chamber can be configured such that a portion of cells can be positioned at least about 1.5 mm from an external wall of the device (i.e., about 1.5 mm away from an external nutrient supply). For example, the cell chamber can have a tubular configuration having a length and a diameter wherein each of these dimensions is at least about 3 mm (thereby the central core to the chamber is at least about 1.5 mm from the outer wall of the device). | 03-20-2014 |
20140163695 | ARTHROSCOPIC TISSUE SCAFFOLD DELIVERY DEVICE - A small diameter delivery device capable of delivering a tissue loaded scaffold arthroscopically to a tissue defect or injury site without reducing the pressure at the injury site is provided. The scaffold delivery device of the present invention comprises a plunger system that includes two main components: an insertion tube and an insertion rod. The insertion tube has a flared proximal end for holding a tissue scaffold prior to delivery. An elongate, hollow body extends from the flared proximal end to a distal end of the insertion tube, and defines a passageway that extends through the body for delivery of the tissue scaffold. The insertion rod has an elongate body that extends into a handle at a proximal end and a tip at a distal end. The insertion rod is configured to be removably disposed within the insertion tube for sliding along the passageway to effect delivery of the tissue scaffold through the insertion tube. | 06-12-2014 |
20140178988 | Differentiated Progeny of Clonal Progenitor Cell Lines - Aspects of the present invention include methods and compositions related to the production and use of embryonic progenitor cell types useful in the generation of cartilage, bone, choroid plexus, tendon, lipasin-secreting adipocytes, and other differentiated cell types useful in research and therapy. | 06-26-2014 |